AMLX Financial Statements

Balance sheet, income statement, cash flow, and dividends for Amylyx Pharmaceuticals Inc (AMLX).


$259.11M Market Cap.

As of 03/04/2025 5:00 PM ET (MRY) • Disclaimer

AMLX Market Cap. (MRY)


AMLX Shares Outstanding (MRY)


AMLX Assets (MRY)


Total Assets

$193.63M

Total Liabilities

$28.87M

Total Investments

$99.11M

AMLX Income (MRY)


Revenue

$87.37M

Net Income

-$301.74M

Operating Expense

$277.47M

AMLX Cash Flow (MRY)


CF Operations

-$167.65M

CF Investing

$75.65M

CF Financing

$348.00K

AMLX Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$0

0%

0%

0%

-

2022

$0

0%

0%

0%

-

2021

$0

-

0%

0%

-

2020

$0

-

-

0%

-

AMLX Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$193,634,000 (-62.58%)

$517,454,000 (32.19%)

$391,453,000 (270.64%)

$105,614,000 (648.82%)

Assets Current

$189,432,000 (-59.23%)

$464,666,000 (21.60%)

$382,133,000 (264.11%)

$104,951,000 (669.49%)

Assets Non-Current

$4,202,000 (-92.04%)

$52,788,000 (466.39%)

$9,320,000 (1305.73%)

$663,000 (42.58%)

Goodwill & Intangible Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Shareholders Equity

$164,765,000 (-61.99%)

$433,432,000 (27.25%)

$340,607,000 (325.32%)

-$151,168,000 (-126.55%)

Property Plant & Equipment Net

$2,732,000 (-57.39%)

$6,411,000 (-21.19%)

$8,135,000 (1616.24%)

$474,000 (213.91%)

Cash & Equivalents

$78,837,000 (-53.87%)

$170,920,000 (170.25%)

$63,245,000 (25.54%)

$50,380,000 (285.58%)

Accumulated Other Comprehensive Income

-$92,000 (-146.70%)

$197,000 (329.07%)

-$86,000 (-1055.56%)

$9,000 (0%)

Deferred Revenue

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Investments

$99,110,000 (-50.73%)

$201,161,000 (-29.27%)

$284,419,000 (519.28%)

$45,927,000 (0%)

Investments Current

$99,110,000 (-50.73%)

$201,161,000 (-29.27%)

$284,419,000 (519.28%)

$45,927,000 (0%)

Investments Non-Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Inventory

$0 (0%)

$83,280,000 (752.49%)

$9,769,000 (0%)

$0 (0%)

Trade & Non-Trade Receivables

$447,000 (-98.88%)

$40,050,000 (161.66%)

$15,306,000 (0%)

$0 (0%)

Trade & Non-Trade Payables

$2,939,000 (-86.68%)

$22,061,000 (252.58%)

$6,257,000 (43.12%)

$4,372,000 (21.01%)

Accumulated Retained Earnings (Deficit)

-$606,692,000 (-98.95%)

-$304,949,000 (13.91%)

-$354,220,000 (-127.29%)

-$155,845,000 (-129.47%)

Tax Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Debt

$1,981,000 (-53.25%)

$4,237,000 (-32.50%)

$6,277,000 (0%)

$0 (0%)

Debt Current

$1,518,000 (-32.74%)

$2,257,000 (10.64%)

$2,040,000 (0%)

$0 (0%)

Debt Non-Current

$463,000 (-76.62%)

$1,980,000 (-53.27%)

$4,237,000 (0%)

$0 (0%)

Total Liabilities

$28,869,000 (-65.64%)

$84,022,000 (65.25%)

$50,846,000 (191.70%)

$17,431,000 (98.83%)

Liabilities Current

$28,406,000 (-65.38%)

$82,042,000 (76.02%)

$46,609,000 (167.93%)

$17,396,000 (137.46%)

Liabilities Non-Current

$463,000 (-76.62%)

$1,980,000 (-53.27%)

$4,237,000 (12005.71%)

$35,000 (-97.57%)

AMLX Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$87,371,000 (-77.06%)

$380,786,000 (1612.94%)

$22,230,000 (7700.00%)

$285,000 (-56.15%)

Cost of Revenue

$124,633,000 (389.89%)

$25,441,000 (750.02%)

$2,993,000 (0%)

$0 (0%)

Selling General & Administrative Expense

$114,331,000 (-39.30%)

$188,356,000 (48.16%)

$127,128,000 (226.53%)

$38,933,000 (158.50%)

Research & Development Expense

$104,084,000 (-18.80%)

$128,187,000 (37.17%)

$93,450,000 (112.19%)

$44,040,000 (79.07%)

Operating Expenses

$277,469,000 (-12.34%)

$316,543,000 (43.51%)

$220,578,000 (165.84%)

$82,973,000 (109.24%)

Interest Expense

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Income Tax Expense

-$393,000 (-107.82%)

$5,026,000 (549.35%)

$774,000 (0%)

$0 (0%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

-$301,743,000 (-712.42%)

$49,271,000 (124.84%)

-$198,375,000 (-125.60%)

-$87,931,000 (-107.97%)

Net Income to Non-Controlling Interests

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

-$301,743,000 (-712.42%)

$49,271,000 (124.84%)

-$198,375,000 (-125.60%)

-$87,931,000 (-107.97%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

-$301,743,000 (-712.42%)

$49,271,000 (124.84%)

-$198,375,000 (-125.60%)

-$87,931,000 (-107.97%)

Weighted Average Shares

$68,142,158 (1.35%)

$67,234,465 (14.94%)

$58,495,587 (788.13%)

$6,586,349 (8.37%)

Weighted Average Shares Diluted

$68,142,158 (-2.64%)

$69,991,340 (19.65%)

$58,495,587 (788.13%)

$6,586,349 (8.37%)

Earning Before Interest & Taxes (EBIT)

-$302,136,000 (-656.45%)

$54,297,000 (127.48%)

-$197,601,000 (-124.72%)

-$87,931,000 (-119.87%)

Gross Profit

-$37,262,000 (-110.49%)

$355,345,000 (1747.20%)

$19,237,000 (6649.82%)

$285,000 (-56.15%)

Operating Income

-$314,731,000 (-911.12%)

$38,802,000 (119.27%)

-$201,341,000 (-143.49%)

-$82,688,000 (-111.99%)

AMLX Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

$75,654,000 (-17.81%)

$92,053,000 (138.52%)

-$238,988,000 (-414.99%)

-$46,406,000 (-30632.45%)

Net Cash Flow from Financing

$348,000 (-90.18%)

$3,543,000 (-99.18%)

$431,789,000 (172.41%)

$158,506,000 (238.52%)

Net Cash Flow from Operations

-$167,647,000 (-1506.55%)

$11,919,000 (106.63%)

-$179,871,000 (-140.47%)

-$74,799,000 (-103.83%)

Net Cash Flow / Change in Cash & Cash Equivalents

-$92,083,000 (-185.52%)

$107,675,000 (736.96%)

$12,865,000 (-65.52%)

$37,314,000 (274.08%)

Net Cash Flow - Business Acquisitions and Disposals

-$36,203,000 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Cash Flow - Investment Acquisitions and Disposals

$112,014,000 (20.07%)

$93,294,000 (139.45%)

-$236,462,000 (-413.46%)

-$46,053,000 (0%)

Capital Expenditure

-$157,000 (87.35%)

-$1,241,000 (50.87%)

-$2,526,000 (-615.58%)

-$353,000 (-133.77%)

Issuance (Repayment) of Debt Securities

$0 (0%)

$0 (0%)

$0 (0%)

$25,846,000 (53.69%)

Issuance (Purchase) of Equity Shares

$2,132,000 (-69.52%)

$6,994,000 (-98.39%)

$434,636,000 (126616.03%)

$343,000 (614.58%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

-$438,000 (-373.75%)

$160,000 (346.15%)

-$65,000 (-600.00%)

$13,000 (0%)

Share Based Compensation

$33,038,000 (-11.09%)

$37,161,000 (71.14%)

$21,714,000 (592.41%)

$3,136,000 (1190.53%)

Depreciation Amortization & Accretion

$904,000 (-16.91%)

$1,088,000 (123.41%)

$487,000 (836.54%)

$52,000 (5100.00%)

AMLX Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

-42.60% (-145.66%)

93.30% (7.86%)

86.50% (-13.50%)

100.00% (0.00%)

Profit Margin

-345.40% (-2777.52%)

12.90% (101.45%)

-892.40% (97.11%)

-30853.00% (-374.33%)

EBITDA Margin

-344.80% (-2477.93%)

14.50% (101.64%)

-886.70% (97.12%)

-30834.70% (-401.17%)

Return on Average Equity (ROAE)

-127.50% (-1128.23%)

12.40% (114.35%)

-86.40% (-207.06%)

80.70% (-12.09%)

Return on Average Assets (ROAA)

-101.10% (-1044.86%)

10.70% (114.46%)

-74.00% (49.63%)

-146.90% (69.90%)

Return on Sales (ROS)

-345.80% (-2518.18%)

14.30% (101.61%)

-888.90% (97.12%)

-30853.00% (-401.46%)

Return on Invested Capital (ROIC)

-215.00% (-1042.98%)

22.80% (117.76%)

-128.40% (75.92%)

-533.30% (62.21%)

Dividend Yield

0% (0%)

0% (0%)

0%

-

Price to Earnings Ratio (P/E)

-0.85 (-104.23%)

20.16 (284.99%)

-10.9

-

Price to Sales Ratio (P/S)

2.95 (13.43%)

2.6 (-97.33%)

97.23

-

Price to Book Ratio (P/B)

1.57 (-31.40%)

2.29 (-68.10%)

7.19

-

Debt to Equity Ratio (D/E)

0.17 (-9.79%)

0.19 (30.20%)

0.15 (229.57%)

-0.12 (12.21%)

Earnings Per Share (EPS)

-4.43 (-706.85%)

0.73 (121.53%)

-3.39 (74.61%)

-13.35 (-91.81%)

Sales Per Share (SPS)

1.28 (-77.37%)

5.66 (1390.53%)

0.38 (783.72%)

0.04 (-59.81%)

Free Cash Flow Per Share (FCFPS)

-2.46 (-1649.06%)

0.16 (105.10%)

-3.12 (72.67%)

-11.41 (-88.19%)

Book Value Per Share (BVPS)

2.42 (-62.49%)

6.45 (10.72%)

5.82 (125.37%)

-22.95 (-109.05%)

Tangible Assets Book Value Per Share (TABVPS)

2.84 (-63.07%)

7.7 (15.00%)

6.69 (-58.27%)

16.04 (590.87%)

Enterprise Value Over EBIT (EV/EBIT)

-1 (-106.25%)

16 (233.33%)

-12

-

Enterprise Value Over EBITDA (EV/EBITDA)

-0.63 (-104.01%)

15.58 (230.85%)

-11.9

-

Asset Turnover

0.29 (-64.48%)

0.82 (893.98%)

0.08 (1560.00%)

0.01 (-93.33%)

Current Ratio

6.67 (17.74%)

5.66 (-30.92%)

8.2 (35.90%)

6.03 (224.01%)

Dividends

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$167,804,000 (-1671.49%)

$10,678,000 (105.85%)

-$182,397,000 (-142.70%)

-$75,152,000 (-103.95%)

Enterprise Value (EV)

$188,397,911 (-78.16%)

$862,652,324 (-63.24%)

$2,346,472,255

-

Earnings Before Tax (EBT)

-$302,136,000 (-656.45%)

$54,297,000 (127.48%)

-$197,601,000 (-124.72%)

-$87,931,000 (-107.97%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

-$301,232,000 (-643.89%)

$55,385,000 (128.10%)

-$197,114,000 (-124.30%)

-$87,879,000 (-119.75%)

Invested Capital

$88,372,000 (-67.11%)

$268,729,000 (-6.65%)

$287,876,000 (660.81%)

$37,838,000 (878.08%)

Working Capital

$161,026,000 (-57.92%)

$382,624,000 (14.04%)

$335,524,000 (283.22%)

$87,555,000 (1286.90%)

Tangible Asset Value

$193,634,000 (-62.58%)

$517,454,000 (32.19%)

$391,453,000 (270.64%)

$105,614,000 (648.82%)

Market Capitalization

$259,110,911 (-73.93%)

$993,861,324 (-59.40%)

$2,448,167,255

-

Average Equity

$236,678,250 (-40.49%)

$397,711,250 (73.22%)

$229,592,500 (310.74%)

-$108,946,500 (-136.63%)

Average Assets

$298,491,500 (-35.31%)

$461,396,000 (72.07%)

$268,143,500 (347.96%)

$59,859,000 (591.05%)

Invested Capital Average

$140,550,500 (-40.92%)

$237,912,000 (54.65%)

$153,842,250 (833.08%)

$16,487,500 (481.77%)

Shares

68,547,860 (1.53%)

67,517,753 (1.90%)

66,256,218 (19.99%)

55,216,013 (0.00%)